论文部分内容阅读
目的检测各型卵巢肿瘤患者血清中可溶性CD30(sCD30)和CD40(sCD40)配体和受体蛋白水平及其与该疾病的关系,为该疾病的临床诊治提供依据。方法研究队列包括60例卵巢肿瘤患者[含30例浆液性囊腺瘤,13例成熟性畸胎瘤和17例浆液性囊腺癌(卵巢癌)患者]和30例健康女性志愿者。ELISA法检测研究对象外周静脉血中sCD30/sCD30L、sCD40/sCD40L各自蛋白质量浓度。结果 3类卵巢肿瘤患者血清sCD30/sCD30L质量浓度均显著高于对照,其中以卵巢癌患者血清质量浓度最高。3类卵巢肿瘤患者sCD40/sCD40L血清水平也均高于对照,其中卵巢癌患者sCD40质量浓度最高而成熟型畸胎瘤患者的sCD40L蛋白水平最高。结论研究结果提示卵巢肿瘤患者sCD30、sCD30L、sCD40可作为卵巢癌患者的早期诊断潜在指标,但这些指标的最终是否能应用于临床仍有待进一步证实。
Objective To detect the serum levels of soluble CD30 (sCD30) and CD40 (sCD40) ligand and receptor protein in patients with various types of ovarian tumors and their relationship with the disease, and provide evidence for the clinical diagnosis and treatment of the disease. Methods The cohort included 60 patients with ovarian tumors [including 30 cases of serous cystadenoma, 13 cases of mature teratoma and 17 cases of serous cystadenocarcinoma (ovarian cancer)] and 30 healthy female volunteers. The concentrations of sCD30 / sCD30L and sCD40 / sCD40L protein in the peripheral venous blood of the study subjects were measured by ELISA. Results The serum concentrations of sCD30 / sCD30L in three types of ovarian cancer patients were significantly higher than those in controls, with the highest serum concentration of ovarian cancer patients. The serum levels of sCD40 / sCD40L in three types of ovarian cancer patients were also higher than the control, of which the highest concentration of sCD40 was found in ovarian cancer patients and the highest in mature teratoma patients. Conclusions The results suggest that sCD30, sCD30L and sCD40 in patients with ovarian cancer can be used as potential indicators for early diagnosis of ovarian cancer patients. However, whether these indicators can be applied to clinical trials remains to be confirmed.